2 results about "Cataract patient" patented technology

The present application relates to the technical field of medical health information and speech synthesis, and specifically discloses an intelligent voice reminding system for medication compliance of cataract patients, which comprises a user interaction terminal, a cloud collaborative processing platform and a medical data interface. The user interaction terminal determines the user's interactive state through multi-modal perception and local behavior recognition and reports it; the cloud platform dynamically decides the reminding time and content strategy through a dynamic strategy decision unit based on the user portrait, the medication task and the user state, and synthesizes personalized voice content by a multi-modal content generation unit for broadcasting. The system realizes precise timing reminding by sensing the user state, and dynamically generates differentiated reminding content based on the personalized portrait, effectively alleviating reminding fatigue, improving the acceptance of reminding and the efficiency of medication compliance management.

This invention provides an application of type I interferon signaling pathway inhibitors in the preparation of drugs for treating age-related cataracts. By inhibiting type I interferon receptors, it can precisely intervene in the aging mechanism of lens epithelial cells, block the transmission of aging signals, and directly improve lens transparency, exhibiting higher therapeutic efficacy and targeting. The use of IFNAR inhibitors can effectively reverse the aging phenotype caused by STEAP3 deficiency, restore the proliferative capacity of lens epithelial cells, thereby maintaining lens transparency, significantly reducing surgical risks, and providing patients with an early intervention opportunity, delaying the onset and progression of cataracts. IFNAR inhibitors, through precise intervention in specific signaling pathways, have more significant therapeutic effects, and due to their targeting, have fewer side effects and are safer. They can not only improve existing cataracts but also play a preventive and delaying role in the early stages of cataracts. For patients with mild cataracts, the use of type I interferon receptor inhibitors can avoid premature surgical treatment, reducing patient dependence on surgery and also reducing the costs and risks associated with surgery.